Nasus Pharma Ltd.
NSRXHealthcare|Medical - Pharmaceuticals|IL
$2.82
-0.09 (-3.09%)
DCF Value
$0.06
Tangible Book / Share
$0.99
Cash / Share
$1.07
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07868861 A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults | Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-induced Nausea and Vomiting (RINV) | P1 | Recruiting | 12 | Open-label | NS003 Ondansetron HCl microspheres powder for nasal application, Ondansetron Solution for IV infusion 8mg |
| NCT07045701 FMXIN002 in Patients at Risk of Anaphylaxis | Anaphylaxis Food | P2P3 | By Invite | 30 | RCT, Double-blind | — |
| NCT06205134 Comparative Bioavailability of Intranasal Epinephrine | Anaphylaxis, Anaphylactic Reaction | P1P2 | Completed | 12 | RCT, Open-label | A: Epinephrine injection, B: FMXIN002 3.6mg, C: FMXIN002 4.0mg |
| NCT07228325 Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis | Anaphylaxis, Allergy | P1P2 | By Invite | 50 | RCT, Open-label | FMXIN002 single dose, Epinephrine autoinjector single dose, FMXIN002 single dose + NAC, Epinephrine autoinjector double dose, FMXIN002 double dose, FMXIN002 double dose + NAC |
| NCT04696822 Bioavailability of Nasal Epinephrine | Anaphylaxis | P1 | Completed | 12 | Open-label | Epinephrine Nasal Product, 1.6 mg, Epinephrine nasal product, 1.6 mg + allergen, Epinephrine Injection 0.3 mg, Epinephrine Nasal Product, 3.2 mg, Epinephrine Nasal Product, 3.2 mg + allergen |
| NCT04713709 A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder | Opioid Overdose | P1 | Completed | 46 | RCT, Open-label | — |
| NCT05252468 COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19). | COVID-19, Upper Respiratory Tract Infections | N/A | Completed | 693 | RCT, Single-blind | — |